- Home
- ALTS vs ADAG Comparison
ALTS vs ADAG Comparison
Compare ALTS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- ADAG
- Stock Information
- Founded
- ALTS 1976
- ADAG 2011
- Country
- ALTS United States
- ADAG China
- Employees
- ALTS N/A
- ADAG N/A
- Industry
- ALTS
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- ADAG Health Care
- Exchange
- ALTS NYSE
- ADAG Nasdaq
- Market Cap
- ALTS 84.1M
- ADAG 85.9M
- IPO Year
- ALTS N/A
- ADAG 2021
- Fundamental
- Price
- ALTS $5.45
- ADAG $1.77
- Analyst Decision
- ALTS
- ADAG Strong Buy
- Analyst Count
- ALTS 0
- ADAG 1
- Target Price
- ALTS N/A
- ADAG $5.00
- AVG Volume (30 Days)
- ALTS 249.5K
- ADAG 24.0K
- Earning Date
- ALTS 11-12-2024
- ADAG 03-09-2025
- Dividend Yield
- ALTS N/A
- ADAG N/A
- EPS Growth
- ALTS N/A
- ADAG N/A
- EPS
- ALTS N/A
- ADAG N/A
- Revenue
- ALTS $7,110,000.00
- ADAG $815,746.00
- Revenue This Year
- ALTS N/A
- ADAG N/A
- Revenue Next Year
- ALTS N/A
- ADAG $2.70
- P/E Ratio
- ALTS N/A
- ADAG N/A
- Revenue Growth
- ALTS N/A
- ADAG N/A
- 52 Week Low
- ALTS $0.50
- ADAG $1.74
- 52 Week High
- ALTS $7.09
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- ALTS 59.84
- ADAG 37.20
- Support Level
- ALTS $5.27
- ADAG $1.76
- Resistance Level
- ALTS $6.59
- ADAG $1.89
- Average True Range (ATR)
- ALTS 0.78
- ADAG 0.12
- MACD
- ALTS -0.09
- ADAG -0.01
- Stochastic Oscillator
- ALTS 43.41
- ADAG 2.94
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.